Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.46 |
| ▸ | PYGL | P06737 | 9/20 | 0.45 |
| ▸ | CHAT | P28329 | 1/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | KDM4B | O94953 | 1/20 | 0.44 |
| ▸ | GUSB | P08236 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3776583 | 1.00 | ALDH1A1 (0.57) | ALDH1A1PTGS2PTGES2PYGLCHAT | |
| SCHEMBL11343214 | 0.82 | PTGES2 (0.51) | ALDH1A1PTGS2PTGES2PYGLCHAT | |
| SCHEMBL11343211 | 0.82 | PTGES2 (0.51) | ALDH1A1PTGS2PTGES2PYGLCHAT | |
| SCHEMBL11329653 | 0.82 | ALDH1A1 (0.50) | ALDH1A1PTGS2PTGES2PYGLCHAT | |
| SCHEMBL11329656 | 0.82 | ALDH1A1 (0.50) | ALDH1A1PTGS2PTGES2PYGLCHAT | |
| SCHEMBL10973260 | 0.78 | ALDH1A1 (0.64) | ALDH1A1PTGS2PYGLCHATKDM4A | |
| SCHEMBL10973255 | 0.78 | ALDH1A1 (0.64) | ALDH1A1PTGS2PYGLCHATKDM4A | |
| SCHEMBL950718 | 0.77 | HSD17B10 (0.52) | PTGS2PTGES2 | |
| SCHEMBL950722 | 0.77 | HSD17B10 (0.52) | PTGS2PTGES2 | |
| SCHEMBL27552743 | 0.76 | ALDH1A1 (0.47) | ALDH1A1PTGS2PYGLCHATKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145380-B2 | Bis-(sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2015-09-29 | — | — | US | disclosed |
| EP-2234993-B1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2012-11-07 | — | — | EP | disclosed |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| EP-2234993-A1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009082347-A1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
| US-4259482-A | NON-SPECIFIC DEPRESSION OF CENTRAL NERVOUS SYSTEM | MEAD JOHNSON & COMPANY (US) | 1981-03-31 | — | — | US | disclosed |
| US-4206142-A | REACTING A STYRYLSULFONYLAMIDINE WITH A BASE | MEAD JOHNSON & COMPANY (US) | 1980-06-03 | — | — | US | disclosed |
| US-4130663-A | ANTITHROMBOGENIC, ANTIHYPERTENSIVE | MEAD JOHNSON & COMPANY (US) | 1978-12-19 | — | — | US | disclosed |
| US-4096183-A | Styrylsulfonylamidines | MEAD JOHNSON & COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
| US-4052455-A | ANALGESICS, BLOOD PLATELET AGGREGATION INHIBITORS | MEAD JOHNSON & COMPANY (US) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | PTGER1, SULT2A1, SULT1E1 | ALDH1A1 61/4885PTGS2 45/4885PTGES2 30/4885 |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | PTGER1, SULT2A1, SULT1E1 | ALDH1A1 78/4885PTGS2 37/4885PTGES2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.